AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32736578
Drug: Brief Motivational
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Motivational Treatment (BMT)
Trial: 35279220
Drug: CO2-laser irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2-laser irradiation in combination with fluoride therapy
Trial: 35279220
Drug: Fluoride therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride therapy alone
Trial: 34381108
Drug: EPA (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA (3 g/d)
Trial: 34381108
Drug: DHA (3
RxNorm normalized name: Gesticare DHA (30) Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (3 g/d)
Trial: 34381108
Drug: High oleic
RxNorm normalized name: High Oleic Sunflower Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High oleic acid sunflower oil (3 g/day, baseline)
Trial: 32609651
Drug: Pharmacological and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological and nonpharmacological treatments
Trial: 32096902
Drug: Percutaneous Mastoid
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous Mastoid Electrical Stimulator (PMES) daily for 45 minutes for three months
Trial: 32096902
Drug: Supraorbital Transcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supraorbital Transcutaneous Stimulator (STS) daily for 20 minutes for three months
Trial: 32278346
Drug: Intramuscular glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular glucocorticoid injection (40 mg triamcinolone acetonide)
Trial: 34105200
Drug: Mass Drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass Drug Administration (MDA)
Trial: 32618245
Drug: focal Mass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: focal Mass Drug Administration (fMDA)
Trial: 33233020
Drug: Contingency management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency management (CM) intervention, 5-week escalating with reset; adjunct to standard smoking cessation treatment.
Trial: 33233020
Drug: Standard smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard smoking cessation treatment (control group not explicitly detailed).
Trial: 33658261
Drug: Telehealth intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telehealth intervention with weekly calls from registered dietitian nutritionists using motivational interviewing
Trial: 34324700
Drug: Fremanezumab monthly
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fremanezumab monthly
Trial: 35361446
Drug: Optimal guideline-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal guideline-directed medical therapy (GDMT) including beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and mineralocorticoid receptor antagonists
Trial: 35361446
Drug: Optimal GDMT
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal GDMT triple therapy use
Trial: 34088228
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of family old age care plus community old age care
Trial: 34965635
Drug: Focused extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Focused extracorporeal shock wave therapy with centrifugal exercise
Trial: 32407535
Drug: MF59‐adjuvanted vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59‐adjuvanted vaccine (FLUAD; Seqirus)
Trial: 32407535
Drug: High‐dose vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High‐dose vaccine (Fluzone High‐Dose; Sanofi Pasteur)
Trial: 32407535
Drug: Standard‐dose inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard‐dose inactivated influenza vaccine (FluQuadri; Sanofi Pasteur)
Trial: 32407535
Drug: Recombinant hemagglutinin
RxNorm normalized name: Influenza B virus B/Brisbane/60/2008 recombinant hemagglutinin antigen
DrugBank: Influenza B virus B/Brisbane/60/2008 recombinant hemagglutinin antigen (DB14418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant hemagglutinin vaccine (Flublok; Sanofi Pasteur)
Trial: 37099983
Drug: Local estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local estrogen therapy
Trial: 35797065
Drug: Motor imagery
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motor imagery combined with structured progressive circuit class therapy
Trial: 35797065
Drug: Health education
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health education combined with structured progressive circuit class therapy
Trial: 33941192
Drug: Evolocumab (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (140 mg every two weeks or 420 mg monthly)
Trial: 32639688
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment only
Trial: 35003321
Drug: Apixaban therapy
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban therapy (research group)
Trial: 35003321
Drug: Standard anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anticoagulation therapy (standard group)
Trial: 33626041
Drug: Complex milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex milk lipid-enhanced (CML-E) group - same formulation enriched with complex milk lipids (≥8 mg gangliosides/day)
Trial: 33626041
Drug: Control -
RxNorm normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control - received standard powdered milk formulation (≥4 mg gangliosides/day)
Trial: 34251840
Drug: Expectancy +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectancy + Drug (told active CBD - given active CBD)
Trial: 34251840
Drug: Drug (told
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug (told inactive - given active CBD)
Trial: 32493111
Drug: Dorsal web
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorsal web space steroid injection
Trial: 32493111
Drug: Palmar midline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmar midline steroid injection
Trial: 34071868
Drug: Multi-ingredient pre-workout
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-ingredient pre-workout supplement (MIPS)
Trial: 34090765
Drug: 20% urea
RxNorm normalized name: UREA 20 g in 100 g TOPICAL CREAM [Nekvnro 20% Urea Cream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% urea cream
Trial: 32399662
Drug: oGLD (intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oGLD (intensive therapy using other glucose-lowering drugs)
Trial: 33901859
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy plus manual therapy (ET plus MT)
Trial: 37032446
Drug: Baricitinib 4
RxNorm normalized name: baricitinib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 4 mg once daily
Trial: 32580813
Drug: Medium-GAA (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-GAA (0.6 g/kg DM)
Trial: 32580813
Drug: High-GAA (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-GAA (0.9 g/kg DM)
Trial: 32580813
Drug: GAA addition
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAA addition (0.3, 0.6, 0.9 g/kg DM)
Trial: 32580813
Drug: Medium-GAA (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-GAA (0.6 g/kg DM) and High-GAA (0.9 g/kg DM)
Trial: 39665235
Drug: Pindolol 15
RxNorm normalized name: pindolol 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol 15 mg
Trial: 36323488
Drug: Biological DMARDs
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological DMARDs treatment
Trial: 36323488
Drug: Prophylaxis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis treatment for Pneumocystis jirovecii
Trial: 32843086
Drug: Third scheduled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third scheduled dose of human monovalent rotavirus vaccine (Rotarix)
Trial: 32886932
Drug: 35 mg
RxNorm normalized name: papain 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg TMZ-modified release
Trial: 32886932
Drug: 70 mg
RxNorm normalized name: silybin 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg TMZ-modified release
Trial: 32886932
Drug: 105 mg
RxNorm normalized name: menthol 105 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 105 mg TMZ-modified release
Trial: 32886932
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of TMZ-modified release
Trial: 33880860
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) treatment, intradermal and subdermal injection weekly for 4-6 sessions.
Trial: 33880860
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (compression and dressing) for chronic venous leg ulcers.
Trial: 33292924
Drug: Early structured
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early structured physiotherapy with a steroid injection
Trial: 32909326
Drug: Sour tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sour tea supplementation (450 mg capsule daily for 8 weeks)
Trial: 32909326
Drug: Placebo (capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (capsule daily for 8 weeks)
Trial: 33684370
Drug: TPEx regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPEx regimen (docetaxel 75 mg/m2, cisplatin 75 mg/m2, cetuximab 400 mg/m2 on day 1 of cycle 1 and 250 mg/m2 weekly thereafter)
Trial: 33684370
Drug: EXTREME regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EXTREME regimen (fluorouracil 4000 mg/m2 on days 1-4, cisplatin 100 mg/m2 on day 1, cetuximab 400 mg/m2 on day 1 of cycle 1 and 250 mg/m2 weekly thereafter)
Trial: 32083490
Drug: LBPT tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LBPT tablet
Trial: 32865944
Drug: Low-dose topical
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose topical creatine cream (3.5 ml)
Trial: 32865944
Drug: High-dose topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose topical creatine cream (7 ml)
Trial: 32865944
Drug: Topical creatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical creatine cream after 7-day supplementation
Trial: 32865944
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream after 7-day supplementation
Trial: 33864070
Drug: Insufficient 25(OH)D
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insufficient 25(OH)D (<30 ng/ml)
Trial: 34167567
Drug: Basiliximab induction
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Basiliximab induction therapy
Trial: 32479321
Drug: Esketamine nasal
RxNorm normalized name: esketamine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine nasal spray + newly initiated oral antidepressant (esketamine+AD)
Trial: 33388426
Drug: Shenmai injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenmai injection (SMI) combined with 5-fluorouracil (5-FU)
Trial: 33388426
Drug: Shenmai injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenmai injection (SMI) combined with neoadjuvant chemotherapy
Trial: 33388426
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (neoadjuvant chemotherapy without SMI)
Trial: 35581440
Drug: Aducanumab (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aducanumab (32 monthly doses, titrated up to 6 mg/kg, cumulative dose of 186 mg/kg)
Trial: 34523872
Drug: Subcutaneous specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous specific immunotherapy (SSI) with whole body bed bug extract
Trial: 36434148
Drug: Mentalization-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization-based treatment for adolescents with CD (MBT-CD)
Trial: 32416981
Drug: Narcotic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narcotic group (received acetaminophen, ibuprofen, and narcotic)
Trial: 32416981
Drug: Nonnarcotic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonnarcotic group (received acetaminophen and ibuprofen)
Trial: 34975069
Drug: Scheduled phosphodiesterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled phosphodiesterase 5 inhibitor (PDE5i) 5 mg tadalafil once a day (OaD) combined with vacuum erectile device (VED)
Trial: 34975069
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of VED and tadalafil OaD
Trial: 34392138
Drug: Adherence monitoring
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adherence monitoring with audiovisual medication reminders
Trial: 36175995
Drug: Maternal fecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal fecal microbiota (FMT) administered orally in breast milk during the first feeding
Trial: 36175995
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment administered orally in breast milk during the first feeding
Trial: 34192430
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ZED1227
Trial: 34192430
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg ZED1227
Trial: 34192430
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ZED1227
Trial: 33632110
Drug: Immediate-release oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release oxycodone 30 mg
Trial: 34395716
Drug: Piperacillin-tazobactam 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin-tazobactam 4.5 g every 6 hours
Trial: 33123968
Drug: Trilaciclib 240
RxNorm normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trilaciclib 240 mg/m2
Trial: 32394350
Drug: TP (docetaxel:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TP (docetaxel: 75 mg/m2 or paclitaxel 175 mg/m2 d1; carboplatin AUC=5, day 1)
Trial: 32394350
Drug: EC (epirubicin:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC (epirubicin: 90 mg/m2; cyclophosphamide: 600 mg/m2, day 1) followed by T (docetaxel: 75 mg/m2 or paclitaxel 175 mg/m2, day 1)
Trial: 34692842
Drug: Lymphocyte active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphocyte active immunotherapy
Trial: 39014463
Drug: Anthracycline therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracycline therapy
Trial: 32311961
Drug: Curcuminoid complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoid complex 500 mg with diclofenac 50 mg
Trial: 32311961
Drug: Diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 50 mg alone
Trial: 35031148
Drug: High-dose quadrivalent
RxNorm normalized name: Fluzone High-Dose Quadrivalent PF 2020-2021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose quadrivalent influenza vaccine (Fluzone High-Dose Quadrivalent; QIV-HD)
Trial: 33475271
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Ranibizumab with Verteporfin)
Trial: 32948224
Drug: Egg white
RxNorm normalized name: EGG WHITE
DrugBank: Egg white (DB10528)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg white hydrolyzate (5 g/day)
Trial: 34246687
Drug: Transmuscular QL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transmuscular QL block with 20 mL 0.375% ropivacaine
Trial: 34246687
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block with 20 mL 0.375% ropivacaine
Trial: 38986212
Drug: Osimertinib 80
RxNorm normalized name: osimertinib 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib 80 mg once daily
Trial: 36533429
Drug: Chemotherapy (control)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (control)
Trial: 33980526
Drug: Early calorie-protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early calorie-protein restriction (6 kcal/kg/day, 0.2-0.4 g/kg/day)
Trial: 33980526
Drug: Standard calorie-protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard calorie-protein targets (25 kcal/kg/day, 1.0-1.3 g/kg/day)
Trial: 34041932
Drug: Experimental vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental vaccine (details not specified)
Trial: 34041932
Drug: Active comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator vaccine with established efficacy of 50%-70%
Trial: 34041932
Drug: Active comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator vaccine with established efficacy of 90%-95%
Trial: 35100468
Drug: Alb‐NC (cerium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alb‐NC (cerium oxide nanoparticles conjugated with albumin; 50 µg/ml)
Trial: 35294962
Drug: Cocoa extract
RxNorm normalized name: Cocoa extract
DrugBank: Cocoa (DB10977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa extract supplement (500 mg flavanols/d, including 80 mg (‐)‐epicatechin)
Trial: 35294962
Drug: Cocoa extract
RxNorm normalized name: Cocoa extract
DrugBank: Cocoa (DB10977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa extract supplement
Trial: 33340120
Drug: mexiletine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mexiletine 300 or 600 mg daily for 4 weeks
Trial: 33409020
Drug: Increasing fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing fluid therapy before surgery
Trial: 34183577
Drug: 4-week TEA
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week TEA treatment
Trial: 34183577
Drug: TEA treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEA treatment
Trial: 32013700
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (AA) 200 mg/kg divided over 24 hours
Trial: 32451267
Drug: Sandblasting (surface
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandblasting (surface treatment)
Trial: 32451267
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (surface treatment)
Trial: 32451267
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser (surface treatment)
Trial: 35178708
Drug: Systemic Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic Family Therapy added to Treatment As Usual
Trial: 34633405
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 mg orally once daily; n=164)
Trial: 34633405
Drug: Prophylactic-dose apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Prophylactic-dose apixaban (2.5 mg orally twice daily; n=165)
Trial: 34633405
Drug: Therapeutic-dose apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Therapeutic-dose apixaban (5 mg orally twice daily; n=164)
Trial: 34633405
Drug: Prophylactic-dose apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Prophylactic-dose apixaban
Trial: 35241226
Drug: Therapeutic-dose apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Therapeutic-dose apixaban
Trial: 32436135
Drug: Mud-bath therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mud-bath therapy with sulfurous-arsenical-ferruginous mineral water
Trial: 34726324
Drug: Metformin 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1500 to 2000 mg daily
Trial: 32979577
Drug: valaciclovir treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valaciclovir treatment for 3 months